There is provided a series of oxime-containing macrocyclic acyl guanidines
of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt
thereof ##STR00001## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, n and X
as defined herein, their pharmaceutical compositions and methods of use.
These novel compounds inhibit the processing of amyloid precursor protein
(APP) by .beta.-secretase and, more specifically, inhibit the production
of A.beta.-peptide. The present disclosure is directed to compounds
useful in the treatment of neurological disorders related to
.beta.-amyloid production, such as Alzheimer's disease and other
conditions affected by anti-amyloid activity.